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1. Abstract 
Chemical substances with a potential to modulate the hormonal system may have harmful 
effects on human or animal health, if they are included in plant protection products. 
Consequently, the new EU plant protection regulation (EC) No 1107/2009 names as one of 
the cut-off criteria that an active substance, safener or synergist shall only be approved if it is 
not considered to have endocrine disrupting properties that may cause adverse effects in 
humans, unless the exposure of humans under realistic proposed conditions of use is 
negligible. However, the new regulation fails to provide measures concerning specific 
scientific criteria for the assessment and decision on substances with endocrine disrupting 
properties. Specific criteria are to be presented by the European Commission within four 
years. 
To address this need, the German Federal Institute for Risk Assessment (BfR) hosted an 
expert workshop to establish assessment and decision criteria in human health risk 
assessment for substances with potential endocrine disrupting properties. It was strongly 
recommended by a majority of workshop participants to replace the preliminary interim 
criteria implemented in the regulation (EC) No 1107/2009 in the decision making process by 
specific scientific criteria at the earliest time possible. Prior to the workshop, a conceptual 
framework for evaluating potentially adverse endocrine effects and their relevance for 
humans under realistically proposed exposure conditions was presented by the BfR. Central 
aspects considered and discussed within this conceptual framework for a tiered decision 
process included the analysis of adversity of effects on the endocrine system, of mechanistic 
data to establish a mode or mechanism of action in animals, and of relevance of such effects 
to humans. The proposal was modified and considered useful as a starting point for the 
development of measures to be adopted in accordance with the regulatory procedure.  
In addition, the importance for extending dosing in toxicity studies to the low dose range and 
to acknowledge critical windows of development as well as a potential need to refine current 
testing guidelines and study designs were critically discussed and the necessity for research 
and further international projects on these issues was emphasised. The recommendations of 
the workshop and proposals for next steps are to be presented to the European Commission 
and EFSA.  
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2. Introduction 
Chemical substances with a potential to modulate the hormonal system may be expected to 
have harmful effects on human or animal health, if they are included in plant protection 
products. Since such endocrine disrupting chemicals have been subject to intensive 
scientific investigation and discussion (for recent overviews see Diamanti-Kandarakis et al. 
2009; Shaw 2009), chemical substances with endocrine disrupting properties have recently 
been specifically addressed in the new European legislation for pesticides, biocides and for 
other chemicals under REACH, respectively (for overviews on regulation see Beronius et al. 
2009; Harvey and Everett 2006).  
 
The new European plant protection products regulation was published on November 24th as 
Regulation (EC) No 1107/2009 and the legislation will fully enter into force in June 2011. 
Among other approval criteria, Regulation (EC) No 1107/2009 names endocrine disrupting 
(ED)1 properties as a cut-off criterion for the approval of substances for use in plant 
protection products (European Council 2009). However, the regulation fails to provide 
specific scientific criteria for the evaluation of substances with potential endocrine disrupting 
properties. Such criteria are to be presented by the Commission within 4 years (by 14 
December 2013). 
 
To address the need to develop specific scientific criteria, the German Federal Institute for 
Risk Assessment (BfR) has proposed a draft concept involving a regulatory decision tree, 
and hosted a workshop to discuss these scientific criteria for the assessment of substances 
displaying endocrine disrupting properties with potential to induce adverse effects on human 
health. The workshop took place from November 11th to November 13th at the premises of 
the Federal Institute for Risk Assessment in Berlin-Marienfelde, Germany. Fifty-three experts 
from 16 countries / international bodies and with different institutional backgrounds 
(academia, regulatory bodies, industry and NGO) participated in the meeting. A list of 
participants is shown in Annex II. 
 
Aims of the workshop were to discuss and develop scientific criteria for the regulatory 
decision on whether or not substances may be regarded as having endocrine disrupting 
properties that may cause adverse health effects in humans, to provide a draft conceptual 
framework for cut-off criteria on approval or disapproval of substances for their use in plant 
protection products, and to propose recommendations and next steps on the improvement 
and endorsement of this decision framework.  
                                               
1
 A list of all abbreviations used in this report is provided in Annex VI. 
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Thus, within the context of development of decision criteria on endocrine disruption, the 
workshop was focussed on regulatory human health risk assessment and on regulation of 
active substances in plant protection products rather than on other areas of chemical 
regulation. It is, however, foreseen that criteria once set for one area of regulation might also 
have implications for other classes of substances, e. g. for biocides or chemicals regulated 
under REACH.  
 
A pre-workshop survey was conducted to identify issues associated with a high level of 
agreement among participants as well as issues of controversy, and to structure and 
facilitate discussion at the workshop accordingly.  
 
The workshop programme (see Annex I for details) comprised a series of presentations on 
the first day followed by group work in breakout groups on the second day. Results of the 
breakout groups were presented at the end of the second day. The workshop was 
concluded by a plenary discussion on the third day.  
 
Introductory presentations summarised the results of the pre-workshop survey and 
introduced a draft conceptual framework suggested by the BfR. The subsequent 
presentations focussed on the issue of endocrine disruption within the new plant protection 
products regulation and related regulations such as REACH, on the informative value of 
studies and methods for analysing potential hazards caused by endocrine disruption, on 
potential targets and mechanisms of endocrine disruption, on the importance of testing the 
appropriate dose range and timing in studies assessing endocrine disrupting chemicals, and 
on assessment of human relevance of endocrine disruption. 
 
Topics of the breakout groups were: Informative value of studies and methods (group I), 
targets and mechanisms of endocrine disruption (group II), dose relevance and criteria for 
adverse effects in animal studies (group III), and human relevance of evidence for endocrine 
disruption (group IV).  
Each group was asked to discuss up to three questions selected from the questionnaire and 
potentially arising related questions. In addition, toxicological data on an example active 
substance of a plant protection product was to be analysed to test the practicability of the 
proposed criteria and decision tree. Furthermore, each group was asked to summarise its 
results and to present future recommendations. Summaries were presented in a plenary 
session on day two. An overview of the results of all breakout groups was presented and 
extensively discussed by the plenum on day three. 
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The following meeting report summarises the results of the breakout groups and the plenary 
discussions at the workshop. It is intended to serve as a protocol integrating different 
opinions rather than as a consensus statement. 
 
3. Workshop results 
3.1. Results of a pre-workshop questionnaire 
Prior to the workshop, a questionnaire was sent out to confirmed participants to obtain their 
input at an early stage, identify pertinent issues, and to prepare and structure the discussion 
in the workshop breakout groups. Based on the questionnaire evaluation, many of the 
questions were scheduled for discussion in breakout groups. Detailed results of the 
questionnaire are presented in Annex III.  
 
3.2. Results of the breakout groups 
The four breakout groups discussed different questions identified by the pre-workshop 
questionnaire, and also related questions if there was time (for detailed results see Annex 
III). In addition, the suggested decision tree was tested for applicability with four different 
examples of active substances in plant protection products. Breakout groups summarised 
their results, and subsequently, the results of the individual breakout groups were presented 
and discussed in a first plenary session on November 12th. An overall summary of the 
results of the breakout groups was discussed in the final plenary session on November 13th. 
Results of both plenary sessions are presented below. Detailed results from the breakout 
groups are presented in Annex IV. 
 
3.3. Results of the plenary sessions 
Major points of discussion related to studies and methods, assessment and decision criteria, 
assessment of human relevance, low dose exposure and timing of exposure, definitions of 
negligible exposure and issues of classification and labelling. The discussion on these 
subjects is summarised below under different headings: 
 
3.3.1. Definitions 
Definitions for endocrine disruption and adversity, which would be feasible in a regulatory 
context, were discussed. A high level of agreement was obtained for implementation of the 
following definitions for regulating plant protection products in the European Union: 
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 Endocrine Disruptor: The WHO/IPCS definition was preferred and also used as a 
working definition for ED during the workshop:  
“An endocrine disruptor (ED) is an exogenous substance or mixture that alters 
function(s) of the endocrine system and consequently causes adverse health effects 
in an intact organism, or its progeny, or (sub) populations (WHO/IPCS 2002)”.2 
 
 Adversity: After controversial discussion in breakout group III, the WHO/IPCS 
definition (extended by the addition of ‘reproduction’) was suggested as a working 
definition for adversity:  
“A change in morphology, physiology, growth, reproduction, development or lifespan 
of an organism which results in impairment of functional capacity or impairment of 
capacity to compensate for additional stress or increased susceptibility to the harmful 
effects of other environmental influences (WHO/IPCS 2004)”.3  
 
3.3.2. Studies and methods 
The intense scientific investigation and discussion of studies and methodology for detection 
of endocrine disrupting effects of substances is reflected by numerous scientific publications 
and overviews (e.g. Baker 2001; Clode 2006; Naciff and Daston 2004) as well as by 
recommendations of methodological frameworks by international bodies such as the OECD 
(OECD 2002). Additionally, internationally harmonised guidelines have been revised (or are 
currently under revision) for enabling better detection of potential endocrine disruptive 
toxicity (Gelbke et al. 2004; Gelbke et al. 2007; Moon et al. 2009; Owens et al. 2007; Owens 
and Koeter 2003).  
 
At the workshop the discussion on studies and methods had a dual focus. On the one hand 
it was asked whether the core studies laid down in the plant protection products legislation, 
which need to be submitted by an applicant for the approval of an active substance for its 
use in a plant protection product, are sufficient to provide evidence for endocrine adverse 
effects. An overview on studies as required by Directive 91/414/EEC (European Council 
1991) is given in Table 1.4 
 
                                               
2 It is noted that this definition was not agreed upon by all participants. A minority of attendants felt that there was no need for 
the definition to contain the term “adverse”, that endocrine disruption should be defined on the basis of what happens in the 
human body resulting from alterations involving endocrine systems, and that any endocrine modulation might have the potential 
to lead to perturbance of human health.  
3 It was stated that some aspects of the definition may be difficult to implement or to apply with the current testing guidelines. 
However, as a working definition, it was regarded feasible. 
4 Directive 91/414/EEC is to be replaced by the new European plant protection products legislation, Regulation (EC) No 
1107/2009. Since this new regulation states that modified data requirements will be provided by June 2011, the old list remains 
valid until replaced.  
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Table 1: List of studies required according to Annex II of the EU plant protection product directive 
91/414/EEC. The listed studies should be conducted in accordance with international guidelines such 
as OECD guidelines. 
 
Annex II Point Area of toxicology Specific studies 
5.1./5.1.1. Absorption, distribution and excretion – following 
both oral and percutaneous administration 
5.1.2. 
Metabolism studies 
in mammals 
Elucidation of metabolic pathways 
5.2./5.2.1. Oral 
5.2.2. Percutaneous 
5.2.3. Inhalation 
5.2.5. Skin and - where appropriate - eye irritation 
5.2.6. 
Acute toxicity 
Skin sensitisation 
5.3./5.3.1. Oral cumulative toxicity (28 day) 
5.3.2. Oral administration – two species, one rodent 
(preferably rat) and one non-rodent, usually 90-
day study 
5.3.3. 
Short term toxicity5 
Other routes if appropriate 
5.4. Mutagenicity Test battery to assess gene mutations, 
chromosomal aberrations and DNA perturbations 
5.5. Long term toxicity 
and carcinogenicity 
Oral long term toxicity and carcinogenicity (rat 
and other mammalian species) – other routes as 
appropriate 
5.6./5.6.1. Multi-generation studies 
5.6.2. 
Reproductive 
toxicity Developmental toxicity studies 
5.7./5.7.1. Neurotoxicity studies in rodents 
5.7.2. 
Neurotoxicity 
studies Delayed polyneuropathy studies 
5.8./5.8.1. Toxicity studies of metabolites  
5.8.2. 
Other toxicological 
studies6 Supplementary studies on the active substance 
5.9./5.9.1. – 
5.9.8. 
Medical data Medical surveillance on manufacturing plant 
personnel; direct observations (e.g. clinical cases 
and poisoning incidences); health records from 
industry and agriculture; epidemiological studies; 
diagnosis of poisoning; allergenicity 
observations; proposed treatment and prognosis 
of expected effects of poisoning 
5.10. Summary of mammalian toxicity and overall evaluation 
 
 
A second focus was on the design of the individual endpoint studies as laid down in 
respective internationally harmonised guidelines such as OECD-guidelines. Here the 
question was raised whether these testing protocols (e.g. for short-term toxicity, 
carcinogenicity, developmental toxicity or reproductive toxicity) are comprehensive enough 
to detect all adverse effects which might be caused by endocrine disruption in mammalian 
test organisms. The recommendations of the workshop are presented below. For a more 
detailed discussion see results of the breakout groups (breakout group I) in Annex IV. 
                                               
5
 For relevant target organs (especially immune, nervous and endocrine systems). If nervous, immune, or endocrine system are 
specific targets in short term studies at dose levels not producing marked toxicity, additional tests including functional testing 
should be considered. 
6
 In certain cases it may be necessary to carry out supplementary studies to further clarify observed effects. These studies 
could include mechanistic investigations on potential effects on the endocrine system. 
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 It was recommended to consider all relevant endocrine mechanisms and systems 
and to integrate mechanism-based analysis. 
(This is, however, already implemented in the directive, as mechanistic studies to clarify a 
mechanism of toxicity may be required). 
 The core data set as laid down in Directive 91/414/EEC was considered to provide 
some evidence on potential adverse effects, but it was stated that it is not clear, if all 
possible aspects of ED would be captured.  
 There were concerns that the existing study designs might not be comprehensive 
enough to detect all adverse effects which might be caused by endocrine disruption 
in mammalian test organisms.  
In this context, the discussion focussed on potential effects in the low dose range (cf. 
3.3.4) and on critical time windows in development. There was concern that, because 
animals may not be evaluated for relevant endpoints during all life stages, certain 
endpoints such as developmental neurotoxicity (DNT) or developmental 
immunotoxicity (DIT) might be missed. Several participants brought forward a 
recommendation that information from extended one-generation studies including 
DNT and DIT modules should be considered for the decision process, if reliable data 
are available. 
 There was also a discussion on the need for additional endpoints to assess all parts 
of the endocrine system. 
 
3.3.3. Assessment and decision criteria  
Preliminary criteria for the decision on ED are laid down in Reg. (EC) No. 1107/2009. These 
criteria suggest that substances that are or have to be classified, in accordance with the 
provisions of Regulation (EC) No 1272/2008, as carcinogenic category 2 and toxic for 
reproduction category 2, shall be considered to have endocrine disrupting properties. In 
addition, substances such as those that have to be classified, in accordance with the 
provisions of Regulation (EC) No 1272/2008, as toxic for reproduction category 2 and which 
have toxic effects on the endocrine organs may be considered to have such endocrine 
disrupting properties. 
These preliminary criteria laid down in Reg. (EC) No. 1107/2009 were criticised as not 
justified from a scientific point of view and it was strongly recommended that specific 
scientific criteria should be developed to replace the interim criteria as soon as possible. 
Therefore, additional criteria were suggested to be integrated into a decision process on 
potential endocrine disruptors. Among these the following were discussed: Adversity, 
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specificity, dose dependency, biological and human relevance. The discussion took place 
mainly in the breakout groups (see Annex IV for more details). Some central aspects are 
however summarised below: 
Discussion on adversity 
 Adversity was favoured as a criterion for assessment and decision of substances 
with endocrine disrupting properties under the new EU plant protection products 
legislation.  
 Since adversity is a central part of several definitions of ED (e.g. Weybridge 1996 or 
WHO/IPCS 2004) it is important to integrate this into a decision process on ED. 
 It was recommended to connect adversity to toxicological relevance.  
 The definition of WHO/IPCS 2004 was suggested for adversity, extended by the 
addition of ‘reproduction’. 
 
Discussion on specificity 
There was a controversial discussion on this criterion, and different opinions were brought 
forward: 
 Effects on the endocrine system or its target organs seen at dose levels causing 
marked generalised toxicity are likely to be the non-specific secondary consequence 
of the marked generalised toxicity and should not be regarded as specifically 
endocrine disruptive. Substances showing those effects should be subject to regular 
risk assessment under the EU PPP Regulation. 
 If endocrine adverse effects occur only above the dose at which a different form of 
toxicity occurs, the apparently more sensitive effect (due to other mechanisms of 
toxicity) could be used for regulatory purposes (derivations of reference values), so 
the endocrine effect could be assumed to be covered by regulation. 
 
The opinions above were strongly opposed by some participants. In particular, 
concern was expressed that critical effects resulting from endocrine disruption, but 
concerning the developing organism, might be regarded as not relevant for the 
decision process if they occurred at dose levels above those causing maternal 
toxicity. 
 It was the opinion of many participants that an effect should not be regarded as being 
non-specific or not relevant purely on the basis of being secondary (the result of a 
primary effect). E. g. liver enzyme induction may lead to a decrease in circulating 
hormone levels, which may in turn have an impact on target organs. Accordingly, 
these attendants advised regulators to consider all effects related to endocrine 
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disruption for the decision process, regardless of whether they may be deemed to be 
primary or secondary. 
 A related statement implied that endocrine disruption should be defined via the 
mechanistic data rather than on the decision of whether an effect is regarded as 
primary or secondary: Among others, one central issue of endocrine disruption is 
generally whether the effect is ultimately a receptor-mediated event. If there is 
evidence that endocrine disruption is the critical effect based on mechanistic studies, 
then effects should be regarded as relevant for the decision process. 
 
Discussion on relevance to humans 
One of the aspects in the decision process on endocrine disrupters involves the 
extrapolation from animal data to the human situation. The BfR proposal initially presented 
to the participants at the beginning of the workshop suggested to implement the human 
relevance framework developed by the IPCS for cancer and non-cancer mode of action 
within the decision process on endocrine disruptors (Boobis et al. 2006; Boobis et al. 2008). 
This framework was critically analysed in detail (Guyton et al. 2008), but has been claimed 
to be useful in a regulatory context (Meek et al. 2008). During the workshop, the IPCS 
human relevance framework was controversially discussed and it was recommended to 
focus on mechanisms of action (in terms of individual mechanistic steps rendering a more 
solid basis of scientific understanding) rather than on a mode of action (which is regarded as 
representing only a more general understanding) in the assessment of human relevance. In 
this context “mechanism of action” should be defined as the totality of mechanistic steps 
necessary for a certain toxic effect while “mode of action” comprises a less detailed 
description of the mechanism or several key events within the mechanism (Guyton et al. 
2008). If, however, it would not be possible to establish a complete mechanism of action, 
mode of action analysis would still be feasible (for a more detailed discussion see below and 
results of breakout group IV):  
 The default assumption is that effects noted in animals are relevant to humans; it can 
be rebutted with additional (mechanistic) data. 
 Mechanism of action is the recommended context for determining relevance. 
 The current regulatory system is based on endpoints. Endpoints observed in toxicity 
studies should be translated into mechanisms where possible. 
 
3.3.4. Low dose effects  
One major point of a controversial discussion in all breakout groups was the question 
whether effects may occur at low doses (e. g. at realistic human exposure levels), below 
those traditionally tested. Low dose effects were also discussed in some of the introductory 
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lectures. Since concern was raised that effects due to non-monotonic dose-response curves 
might be overlooked in current guideline-conform toxicity testing for which doses are 
employed that typically exceed human exposure by orders of magnitude (Beronius et al., 
2009), it was regarded as important to discuss and clarify this issue. In the course of the 
discussion the following points were mentioned / suggested by a number of experts: 
 Part of the participants raised concern that, based on current data sets, endocrine 
effects might be missed for certain compounds in the lower dose range.  
 It was recommended, triggered by evidence, to encourage improvement of testing in 
respect to the low dose range. 
 However, concerns on the robustness of low dose effects were also addressed by 
other participants.  
 Reproducibility of effects and validation would be required for the inclusion of low 
doses in testing guidelines (amendment of existing guidelines). The question on how 
to design a low dose test was raised and the importance of validation emphasised.  
 The need for concrete examples for substances and/or endpoints that are not 
currently captured by the typical range of dose levels used in guideline-testing, to 
decide which endpoints and low dose levels should be included into existing 
guidelines was mentioned by some participants. 
 It was critically mentioned by other participants, that increasing the minimum number 
of dose levels would require more animal testing. In this context it was noted that 
guidelines usually do not dictate dose levels but recommend an appropriate number 
of doses (minimum three) and that the highest dose should induce toxicity.   
 To examine the potential for adverse effects at a low dose level (below a “traditional” 
NOAEL), it was further recommended to develop, validate and apply “new” 
methodology (e. g. array approaches) aiming at identification and interpretation of 
additional mechanistic (receptor-mediated) effects. Clarification on how to do this in 
practice was also recommended. 
 To bring the low dose issue forward in a productive way, several recommendations 
were made: 
 Robust evidence of low dose effects of endocrine disrupting substances was 
considered to be important to be established before regulatory action might 
be taken. This evidence should include reproducibility of effects with the 
same compound in different studies.  
 Funding of international projects for the validation of methods and 
development of new methodology and  
 funding of literature search on evidence for potential low dose effects of 
substances with endocrine disrupting properties were recommended. 
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 The necessity of workshops on low dose issues was considered to be of 
major relevance. 
 
3.3.5. Negligible exposure 
The regulation (EC) No. 1107/2009 states that a substance with endocrine disrupting 
properties should not be approved ‘unless the exposure of humans to that active substance, 
safener or synergist in a plant protection product, under realistic proposed conditions of use, 
is negligible’ (European Council 2009). It states further, that negligible means that the 
product would be used in closed systems or in other conditions excluding contact with 
humans and that residues of the active substance, safener or synergist concerned in food 
and feed do not exceed the default value set in accordance with point (b) of Article 18(1) of 
Regulation (EC) No 396/2005 (European Council 2005), which is 0.01 mg/kg food. At the 
workshop the definition of negligible exposure as laid down in the regulation was critically 
discussed. Many participants disagreed with the setting of a default value, as this would not 
account for different potencies of different substances and because a default value might not 
adequately cover substances which have critical effects below this value. As science-based 
concepts, the margin of exposure (MOE) or the threshold of toxicological concern (TTC) 
were suggested. Both concepts have been discussed for carcinogenic substances in food 
(Barlow and Schlatter 2009; Pratt et al. 2009). The TTC concept is presented in more detail 
by Kroes et al. (2005). Critical points discussed at the workshop were:  
 A maximum residue level (MRL) of 0.01 mg/kg food for all compounds is not a 
health-based scientific decision criterion to protect consumers.  
 Closed systems do not necessarily exclude exposure of bystanders and residents.  
 It was strongly recommended that a science-based definition of negligible exposure 
should be preferred to a default value. 
 
3.3.6. Classification and labelling 
Classification and labelling in the European Union is performed according to Regulation (EC) 
No 1272/2008. It was discussed, whether classification and labelling of ED should be 
performed according to this regulation or whether it would be advisable to develop a new 
system for endocrine disruptors. The following suggestions were made: 
 At first the adopted regulatory system for classification and labelling should be 
applied.  
 In the next phase it was regarded by some participants to be necessary to develop a 
classification system for endocrine disrupting chemicals considering issues such as 
adversity etc. 
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 It was discussed whether a system similar to that applied for mutagenicity, 
carcinogens or reproductive toxicity, or rather a yes/no classification, or a system 
based on level of concern should be recommended.   
 A critical point was the suitability of interim criteria. 
 Preliminary criteria as laid down in Reg. (EC) No. 1107/2009 (Carcinogenic Cat. 
2/Reprotoxic Cat. 2 substances are to be regarded as EDs) were considered as 
not science-based.  
 The necessity was emphasised to develop specific scientific assessment criteria 
to replace the preliminary interim criteria.  
 
3.4. The BfR tiered approach and decision tree  
A tiered approach was suggested by the BfR, intended to reflect a possible decision process 
for substances with potential endocrine disrupting properties in plant protection products 
(original version shown in Annex V). As a more detailed elaboration of this tiered approach a 
draft decision tree was presented including specific science-based criteria such as adversity. 
The workshop discussions have provided recommendations for an improvement of this 
framework. The tiered approach and the decision tree were considered applicable for the 
examples discussed at the workshop and useful as a starting point for the development of 
measures concerning specific scientific criteria for the determination of endocrine disrupting 
properties to be adopted in accordance with the regulatory procedure by the participants of 
the workshop. The modified approach is described in the following (Figure 1 giving an 
overview on the tiered approach and Figure 2 showing a detailed draft decision tree. Colours 
in Figure 2 represent single steps of the tiered approach). In any case, it was recommended 
that the decision should be made on a case-by-case basis and should be based on expert 
judgement. 
 
Step I 
In a first step, the proposal stipulates the analysis of the toxicological data provided by the 
applicant as required in Annex II of Directive 91/414/EEC (see Table 1 for a list of all studies 
required) as a starting point for the decision process. These Annex II toxicity data as well as 
all other available data (including data from peer reviewed scientific journals) would be 
analysed for potential hazards (e.g. carcinogenicity, reproductive or developmental toxicity) 
by the responsible authority. Based on hazards identified by analysis of the respective 
toxicological endpoints, regulatory agencies would suggest classification and labelling of the 
substance in accordance with Regulation (EC) No 1272/2008 (European Council 2008).7 
                                               
7
 It should be noted at this stage that classification and labelling for regulatory purposes has to be made in accordance with 
current legislation and that regulators are legally bound to this legislation. 
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Substances which would have to be labelled as carcinogenic, mutagenic or as reprotoxic 
(CMR) categories 1A and 1B in accordance with Regulation (EC) No. 1272/2008 would be 
excluded from Annex I (banned) as requested by Regulation (EC) No. 1107/2009 at this 
step.8 Since the decision process on classification and labelling regarding CMR may not yet 
be completed, it was recommended during the workshop to also include substances 
proposed to be labelled CMR 1A or 1B into the analysis of endocrine disrupting properties, 
and to clarify their mechanism of toxicity. If a substance proposed to be labelled CMR 1A or 
1B were, in addition, an endocrine disruptor, it would be considered as especially noxious 
(severe).  
 
Step II 
In a second step this endpoint-based analysis would be translated into a mechanism-based 
analysis to the extent possible as recommended during the workshop. At this stage it would 
be required to regard all effects / endpoints separately, and to analyse all available data for 
effects potentially caused by an endocrine active substance, hence to analyse the potential 
endocrine mechanism(s) of the respective substance. Since hormonal regulation is involved 
in virtually all physiological processes of animals, it is crucially important at this stage to 
have criteria at hand to distinguish between physiological and adverse hormonal effects.  
 
The BfR had suggested several potential criteria for the identification of such harmful 
endocrine disrupting effects (Marx-Stoelting et al. 2009). Among these were adversity, 
specificity, dose-dependency as well as human relevance. These criteria were all integrated 
into the original draft decision tree (since a modified version of this decision tree was 
prepared to integrate the results and recommendations of the workshop, the first draft is only 
shown in Figures 3 and 4 of Annex V, while the modified versions are presented in Figures 1 
and 2 in the main document). Since discussion on specificity and dose-dependency was 
controversial, adversity (in combination with toxicological relevance as suggested during the 
workshop) remains the most important criterion for decision on ED for regulation at this 
stage. Adversity should be understood as recommended by the majority of workshop 
participants and as defined by WHO/IPCS 2004.  
 
If there is no evidence for adverse / toxicological relevant effects potentially related to ED, 
the decision tree can be left at this step. If on the other hand effects potentially related to an 
endocrine disruptive mechanism occur, which are regarded as adverse, it will be necessary 
to establish a mode (or better: a mechanism) of action in animals. For this purpose, 
additional mechanistic studies in vivo and in vitro may be required. The default assumption 
                                               
8
 For carcinogenic and reprotoxic substances, Reg. (EC) 1107/2009 also requests comparision to exposure and allows 
approval of a substance if exposure is negligible as defined in point 3.6.3 and 3.6.4 of annex II of the regulation. 
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at this stage is that the mechanism is endocrine. If no mechanistic data are provided or if the 
mechanism of action is shown to be endocrine, the substance may be considered being an 
endocrine disruptor in animals. However, if the mechanistic data clearly show that the 
mechanism of action is not based on endocrine effects, the substance is presumably not an 
endocrine disruptor and the decision tree can be left at this step. 
 
Step III 
In a third step, relevance of effects observed in animal studies for humans will have to be 
analysed. Some participants mentioned that the default assumption at this stage has to be 
that animal findings are relevant to humans.9 Consequently, only if a mechanism of toxicity 
in animals is identified that is clearly not relevant to humans, the decision tree might be left 
at this step.  
 
It was originally suggested to implement the IPCS mode of action framework (Boobis et al. 
2006, 2008) at this step. This was controversially discussed, as there was disagreement 
among some participants on the applicability of this framework (see discussion on human 
relevance). As a consequence, the IPCS framework was not integrated into the proposed 
decision tree, but it was left to the decision of the regulators performing human relevance 
analysis, which human relevance framework should be used. In this context regulators might 
however be bound to regulatory frameworks which are generally accepted by international 
regulatory bodies. 
 
                                               
9
 It should however, be noted that regulatory procedures in the European Union and other international Regulatory Authorities 
have usually considered human relevance as a default assumption. 
BfR Workshop Report  
 
 
17 
 
Figure 1: Modified tiered approach. For the original suggestion see Annex V. This tiered approach 
represents an overview and reflects the way a regulatory decision process may be made in general. A 
more detailed decision tree is shown in Figure 2. 
 
Step IV 
The fourth and last step consists of the decision whether a substance would have to be 
regarded as an endocrine disruptor in a regulatory sense. If, at this stage a substance is 
considered to have endocrine disrupting properties that may cause adverse effects in 
humans, the final decision on approval or disapproval should be made, based on 
assessment of exposure. Approval would only be possible if the exposure of humans under 
realistic proposed conditions of use is negligible as defined by Regulation (EC) No 
1107/2009 in Annex II point 3.6.5. In this context, the need for a more science-based 
definition of negligible exposure, taking into account concepts like the margin of exposure 
(MOE) should be pointed out. 
 
 
II. Analysis of endocrine disruption in animals 
(mechanism-based) 
III. Analysis of relevance for humans 
(default assumption: relevance) 
IV. Decision on endocrine disrupting properties that 
may cause adverse effects in humans if no negligible 
exposure 
I. Evaluation of all available data / relevant endpoints 
 (endpoint-based) 
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Figure 2: Modified detailed draft decision tree. This decision tree is a more detailed elaboration of the 
tiered approach suggested in Figure 1. Colours of boxes represent the relation to the four steps of the 
tiered approach shown in Figure 1. After evaluation of all data an endpoint based hazard analysis is 
conducted (grey boxes). This is followed by an analysis of the mechanisms, which might have caused 
toxicity (green boxes). This mechanistic evaluation includes criteria like adversity as well as the 
establishment of a mode/mechanism of action in animals. If this mechanism is related to ED, its 
relevance to humans will be analysed with the default assumption being relevance to humans (blue 
box). After comparison to exposure a decision is made on ED in the regulatory sense in the last step 
(red boxes). For a detailed description of the decision process see text. A: Category 1A and 1B 
carcinogens and / or reprotoxicants are foreseen to be automatically banned at this stage. To clarify 
the mechanism of toxicity it is recommended to also analyse these substances for endocrine 
disrupting properties. B: Specific target organ toxicity (STOT) can occur after single exposure (SE) or 
repeated exposure (RE) according to Reg. (EC) No. 1272/2008. STOT is a possible label for toxicity 
to any organ. In the context of endocrine disruption, not only effects on organs of the endocrine 
system, but also effects on its target organs, including the immune- or the nervous-system, may be 
regarded as being of particular importance.  
 
 
Discussion 
The discussion on criteria and the decision tree in the plenary sessions and breakout groups 
resulted in the following recommendations (for more details see results of the breakout 
groups in Annex IV. The original decision tree is presented in Annex V): 
 The decision tree was considered useful (with modifications).  
Evidence for adverse / 
toxicologically relevant 
effects potentially related to 
ED? 
NO 
Cancer  
EffectsA
 
Reprotoxic 
EffectsA
 
Spec. Target 
Organ Tox.B
 
No ED 
Relevance of mechanism or mode of 
action to humans?
 
No human 
relevant 
ED 
NO 
Evaluation of all available data  
Additional 
Mechanistic studies 
Mechanism related to ED? NO No ED 
Sufficient information to 
Establish MoA in animals 
YES 
YES 
YES 
Decision: ED according to Annex II 3.6.5 
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 It was recommended that toxicological relevance should be part of the decision on 
adversity (as modified in Figure 2). 
 It was suggested to change the position of step II (original mechanism-based 
analysis of endocrine mechanism in animals) and III (original endpoint based 
analysis of all relevant endpoints) so that the endpoint-based analysis is translated 
into a mechanism-based analysis. 
 It was suggested not to exclude substances labelled CMR categories 1A or 1B from 
the decision process for allowing mechanism based analysis. 
 The use of mechanism of action was preferred to mode of action (mode of action 
does not have to be replaced).  
 The default assumption on human relevance is that findings in animal studies are 
relevant to humans. For a detailed discussion on human relevance see results of 
breakout group IV.  
 It was advised to regard each effect/endpoint separately within the decision process. 
Although a single endpoint, e. g. thyroid tumour development under inducers of 
thyroid hormone metabolism in rodents, may be considered to be less relevant to the 
human situation, other effects/endpoints exerted by the same substance during a 
critical window of development may indeed also be critical to humans. 
 It was recommended to add a question to the boxes on mechanism that specifically 
asks: ‘Is there a relationship to an endocrine mechanism?’  
If no, the substance is not regarded as an ED and an exit should be provided at 
this point. If yes, proceed to the next step. If uncertain, ask for more data or 
default to ED. 
 It was recommended that prior to its adoption, the decision tree should be tested with 
a higher number of compounds including known positive ED compounds and known 
negative controls. 
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4. Summary and recommendations 
The workshop discussions have provided recommendations for criteria for regulatory 
assessment of active substances in plant protection products with potential for adverse 
effects on the human endocrine system. Furthermore, suggestions were made for the 
improvement of the conceptual framework for evaluating potentially adverse endocrine 
effects and their relevance for humans under realistically proposed exposure conditions, 
which was presented by the BfR. The decision tree was considered useful for the scientific 
assessment of active substances in plant protection products with potential to cause adverse 
effects on the human endocrine system to be adopted in accordance with the regulatory 
procedure. It was strongly recommended by the majority of workshop participants to replace 
the preliminary interim criteria implemented in the regulation (EC) No 1107/2009 in the 
decision making process as soon as possible by specific scientific criteria. Among the 
discussed criteria, adversity was the least controversial. WHO/IPCS definitions for adversity 
and endocrine disruptors, respectively, were favoured by a majority of participants as 
working definitions for the meeting.  
 
Besides assessment and decision criteria, the importance of extending dosing in toxicity 
studies to the low dose range and to acknowledge critical windows of development as well 
as a potential need to refine current testing guidelines and study designs were critically 
discussed, but no consensus was reached. Both the necessity for research to test the 
robustness and scope of effects in the low dose range as well as the need to integrate 
further endpoints, including developmental neurotoxicity or developmental immunotoxicity, in 
toxicity testing of substances with endocrine disrupting properties, were emphasised. 
 
Since a definition of negligible exposure is crucial for decision making, different definitions of 
negligible exposure were considered. At the workshop, a more science- based definition was 
favoured over the default value of 0.01 mg/kg food laid down in the new plant protection 
products regulation.  
 
While these recommendations might be implemented within a conceptual framework for a 
tiered decision process on substances with endocrine disrupting properties as a starting 
point for the development of measures to be adopted in accordance with the regulatory 
procedure (see Figures 1 and 2), there were also other suggestions which may be integrated 
into future international projects (e.g. validation of methods for the detection of low dose 
effects) and may be considered in future decision processes. The recommendations for next 
steps are summarised below. 
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1. Presentation of the conclusions of the workshop to the European Commission and 
EFSA 
2. Publication of the workshop scientific results and the conclusions of the workshop by 
the organising committee 
3. Discussion of the recommendations and proposed next steps of the workshop 
together with public, risk managers, NGOs and other stakeholders, e. g. at a BfR 
forum in 2010 
4. Consideration of the relevance of this conceptual framework for a tiered approach by 
OECD and other bodies, e. g. IPCS/WHO 
5. Search for and compilation of practical examples of endocrine disruption that were 
not detected in routine studies  
 
Recommendations for research and further international projects in the future were: 
1. to consider the extension of existing guidelines to better address the issue of ED 
2. to incorporate an appropriate number of dose levels in study designs to determine a 
dose-dependency for relevant endpoints if low dose effects proved to be robust  
3. to concentrate on developmental exposure and life-time assessment  
4. to include research on detection of „changes in state“ that render an organism more 
susceptible to environmental influences 
5. to hold workshops addressing the low dose issue and encourage experimental work 
to clarify the relevance of or clearly establish reproducible effects in the low dose 
range  
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Annex I: Workshop programme 
 
Wednesday, November 11th 2009 
14.00 Shuttle transport Steglitz International Hotel – BfR      
15.00 - 15.10 Welcome  Ursula Banasiak, BfR 
15.10 – 16.00 Introduction and workshop outline Karen Hirsch-Ernst, 
Philip Marx-Stoelting, 
BfR 
16.00 - 16.20 The Community strategy for endocrine 
disruptors – status and priorities  
Patrick Murphy, EU 
Commission 
16.20 - 16.40 Coffee break  
16.40 - 17.20 Informative value of methods  Remi Bars, ECETOC 
17.20 - 18.00 Targets and mechanisms of ED  Jun Kanno, NIHS 
18.00 - 18.40 Dose relevance  Jerry Heindel, NIEHS 
18.40 - 19.20 Human relevance  Ellen Silbergeld, 
JHSPH 
19.20 - 19.35 Using mode of action information to improve 
regulatory decision making 
Richard Lewis, 
Syngenta 
19.45  Get together   
21.30 Shuttle transport BfR – Steglitz International Hotel   
 
Thursday, November 12th 2009 
08.45 Shuttle transport Steglitz International Hotel – BfR  
09.30 - 10.00 Plenary session,  
Break out group briefing  
Moderation: Roland 
Solecki, BfR 
10.00 - 10.15 Coffee break  
10.15 - 12.30 Break out groups: Answering the questions  
12.30 - 13.30 Lunch break  
13.30 - 15.00 Break out groups: Presentation and discussion 
of the case studies 
 
15.00 - 15.15 Coffee break  
15.15 - 16.00 Break out groups: Discussion of 
recommendations and next steps 
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Thursday, November 12th 2009, continued 
16.00 - 16.30 Coffee break  
16.30 - 18.30 Plenary session: Reports from the break out 
groups  
Moderation: Jochen  
Buschmann, ITEM 
and Istvan 
Sebestyen, EFSA  
16.30 - 17.00 Break out group I: Informative value of 
methods  
 
17.00 - 17.30 Break out group II: Targets and mechanisms 
of endocrine disruption  
 
17.30 - 18.00 Break out group III: Dose relevance and 
criteria for adverse effects in animal studies  
 
18.00 - 18.30 Break out group IV: Human relevance of 
evidence for ED  
 
18.30 Shuttle transport BfR – Steglitz International Hotel    
19.30 Public bus service Hotel – Dinner    
20:00 Dinner  
 
 
Friday, November 13th 2009 
08.45 Shuttle transport Steglitz International Hotel – BfR  
09.30 – 10.15 Summary of the results  Karen Hirsch-Ernst 
10.15 – 10.30 Coffee break  
10.30 – 12.00 Plenary discussion  Moderation: Helen 
Hakansson, Karo-
linska Institute and 
Ibrahim Chahoud, 
Charité 
12.00 - 12.30  Concluding remarks and potential next steps  Karen Hirsch-Ernst, 
Roland Solecki, BfR 
12.30  End of workshop (optional: lunch break)  
13.15 Shuttle transport BfR – Steglitz International Hotel   
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Annex II: List of participants 
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Annex III: Results of the questionnaire 
 
In preparation for the workshop a questionnaire was sent out to invited experts. Aims of the 
questionnaire were to facilitate and structure discussion at the workshop and to identify 
issues on which experts confined high level of agreement and consequently, to select 
controversial questions for discussion. The questionnaire was also aimed to integrate 
experts’ opinion into the BfR draft concept for assessment and decision criteria on plant 
protection products with endocrine disrupting properties at an early stage. Of the 
questionnaires sent out 33 (~75%) were returned in time for analysis prior to the meeting (by 
October 23, 2009). Since some participants were nominated for the workshop later, a few 
questionnaires were sent out for informational purposes only and were not included in the 
calculations at the present state. From the results of the survey, an index of agreement (IA) 
was calculated for each question for which three options were given according to the 
following formula:  
IA = (Yes – No) / (Yes + No + Undecided) x 100 [%] 
It is suggested to focus on questions with an IA of below 50% and to regard questions with 
an IA of above 50% as less controversial. The results of the questionnaire, the IA, selected 
comments from participants on single questions and suggestions for further action are 
presented in the summary below. 
 
Question 1: Assignment to breakout groups  
Assignment of breakout groups will be presented in a different document. 
 
Question 2: Which definition of ED do you prefer? 
A majority of 24 participants chose Weybridge or IPCS as the preferred definition of ED. 
Since these definitions differ only slightly (i.e. IPCS mentions subpopulations), the IPCS 
definition was chosen as a working definition. The IA was not calculated, since more than 
three options were given here. 
 
Comments from single participants: 
− Any definition is preferred, as long as it also defines "adverse". 
 
Action suggested: IPCS definition is proposed to be regarded as working-definition. No 
detailed discussion foreseen. 
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Figure 1: Results for the question on preferred definition for ED. N=33; deviations from this number 
can be explained by some participants who did not answer this question at all. 
 
Question 3: How would you define a low dose effect? 
Experts had diverging opinions on definition of low dose as presented in Figure 2. The IA in 
favour of realistic human exposure level as the definition is 20%. 
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Figure 2: Results for the question on preferred definition for low dose. N=33; deviations from this 
number can be explained by some participants who did not answer this question at all. 
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Comments/suggestions from participants: 
• A low dose effect is an effect occurring in the µg or even the ng range. 
 
• An effect can only be lower than the NOEL on a limited dose-response curve. 
 
• It is wise to choose a working definition, in part because it is sometimes difficult to 
know or estimate with precision the level to which humans are exposed. 
 
Action suggested: Should be discussed in breakout group III. In addition a regulatory and / 
or political decision on how to integrate low dose in current international guidelines and 
protocols for toxicity testing is required. 
 
Question 4: What is a negligible exposure level? 
Several options were given. Three major ones can be summarized: negligible is below a 
defined value (e.g. 0.01 mg/kg foodstuffs as given in Directive EC 396/2005) or the TTC-
(threshold of toxicological concern)-concept is applied or the MOE (margin of exposure). 
Participants were undecided about the best concept to be applied as presented in Figure 3 
below. However, MOE and TTC were favoured over the defined maximum residue level 
given in Directive EC 396/2005 and as provided in the new European plant protection 
products legislation. Since more than three options were given, no IA was calculated here. 
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Figure 3: Results for the question on negligible exposure. N=33; deviations from this number can be 
explained by some participants who did not answer this question at all. 
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Comments from participants: 
• If a chemical is not tested, then the threshold for concern is not known.  
 
• Negligible exposure level could mean different things such as exposure to a very 
limited population but also that the chemical is handled so the emission is kept to a 
minimum.  
 
Action suggested: Since negligible exposure is a critical term in the new legislation, there is 
a need for discussion. Therefore, this question should be discussed in breakout group IV. 
 
Question 5: How can 'adverse' be defined? 
Definition of adversity is crucial if adversity is to be considered as one important criterion for 
decision on plant protection products with endocrine disrupting properties. A majority of 
responders favoured ECETOC and EPA definitions. 
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Figure 4: Results for the question on preferred definition for adverse. N=33; deviations from this 
number can be explained by some participants who did not answer this question at all. 
 
Comments from participants: 
• OECD/IPCS definition is preferred (this comment was given by several participants). 
 
• Consideration of the definition in the US NRC Toxicity Testing in the 21st Century is 
recommended. 
 
(IPCS definition: A change in morphology, physiology, growth, development or lifespan of an 
organism which results in impairment of functional capacity or impairment of capacity to 
compensate for additional stress or increase insusceptibilitiy to the harmful effects of other 
environmental influences.) 
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Taken the results and comments together, the following synthesis of definitions is 
suggested: A biochemical change, functional impairment, or pathological lesion (in response 
to a stimulus) that either singly or in combination affects the performance of the whole 
organism or reduces the organism’s ability to respond to additional environmental challenge.  
 
Action suggested: To be discussed and decided during the workshop. Should be discussed 
in detail in breakout group III. A synthesis of ECETOC / EPA and IPCS may be suggested. 
 
Question 6: Are the core studies laid down in point 5.3, 5.5 and 5.6 of Table 1 
sufficient to provide any evidence on potential effects on the endocrine system in 
mammals? 
A majority of experts agreed, that the core studies on short-term toxicity, reproductive and 
developmental toxicity, long term toxicity and carcinogenicity are sufficient to provide any 
evidence on effects on the endocrine system in mammals. However, the IA equalled 48.4%.  
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Figure 5: Results for the question on core studies. N=33; deviations from this number can be 
explained by some participants who did not answer this question at all. IA =48.4%. 
 
Comments from participants: 
• If you mean that the core studies will provide evidence on potential effects on the 
endocrine system for any type of endocrine toxicity my answer is No. 
 
• More end-points, including high throughput data/signatures are needed in addition to 
the existing studies. 
 
• The two generation reproductive effect studies of modern design that incorporate 
endocrine sensitive endpoints are the most useful of required studies.  
 
Action suggested: Should be discussed in breakout group I. 
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Question 7: Is a stepwise approach feasible that, triggered by evidence observed in 
core studies mentioned, additional mechanistic studies will be required to clarify the 
potential endocrine mechanism and its relevance to humans? 
Participants basically agreed that a tiered approach is feasible. The index of agreement was 
75%. The development of a more detailed draft decision tree and its discussion will therefore 
be a major scope of the workshop. 
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Figure 6: Results for the question on a stepwise/tiered approach. N=33; deviations from this number 
can be explained by some participants who did not answer this question at all. IA=75%. 
 
Comments from participants: 
• Current tests are not fully adequate and they should be augmented with more 
sensitive screens.  
 
Action suggested: A stepwise approach is favoured by a vast majority of participants. BfR 
will therefore be suggesting a more detailed draft decision tree to be tested on some 
examples and to be discussed during the workshop.  
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Question 8: Are existing study designs comprehensive enough to detect endocrine 
effects? 
16 of 33 responders answered ‘yes’ (see Figure 7 below). 
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Figure 7: Results for the question on existing study designs. N=33; deviations from this number can 
be explained by some participants who did not answer this question at all. IA=42.3%. 
 
Comments from participants: 
• There are existing study designs, but not necessarily the test guidelines of OECD or 
similar organisations. 
 
• More knowledge is needed to understand the links between early developmental 
landmarks and functional consequences. 
 
• Rephrase: comprehensive enough to detect effects that may result from endocrine 
mechanisms. 
 
• Existing tests still do not do so adequately. Some, like the two-generation 
mammalian test, can be improved by adding endocrine sensitive developmental 
endpoints such as time to vaginal opening and preputial separation or anogenital 
distance. 
 
 
Action suggested: Should be discussed in breakout group I. 
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Question 9: Is it appropriate to acknowledge cumulative effects, resulting from 
exposure to substances displaying a common mode of action or targeting the same 
hormonal system in the regulatory framework? 
Approximately three quarters of responders agreed that acknowledging cumulative effects is 
important. The IA was 57.1%.  
0
5
10
15
20
25
Yes No No preference
 
Figure 8: Results for the question on acknowledgement of cumulative effects. N=33; deviations from 
this number can be explained by some participants who did not answer this question at all. 
 
Comments from participants: 
• It has to be a case-by-case decision. 
 
• Cumulative risk assessment is not solely based on hazards, but takes both hazard 
and exposure into account. If substances are disapproved purely due to their hazard 
potential, cumulative risk assessment for endocrine disrupting pesticides in food will 
only need to be performed for mixtures with individual residues below 0.010 mg/kg 
foodstuff. 
 
• If we are going to be adequately protective of human health we must reflect these in 
our risk assessments to the extent possible. 
 
Action suggested: Since criteria for single substances have to be developed prior to 
discussing how to acknowledge cumulative effects of several substances, it is suggested to 
leave this topic open for future discussion at a different workshop. 
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Question 10: Can adversity be used as a criterion to analyse potential endocrine 
disrupting properties? 
Adversity was the criterion for assessment of and decision on plant protection products with 
potential endocrine disrupting properties for which the highest level of agreement was 
obtained. The IA was 73.3%. 
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Figure 9: Results for the question on adversity as a criterion for assessment and decision on ED. 
N=33; deviations from this number can be explained by some participants who did not answer this 
question at all. IA=73.3%. 
 
Comments from participants: 
• No, recognition of 'adversity' may change rapidly in accordance with increment in 
knowledge of basic biology. 
 
• Anything that is not adverse is also not disrupting. 
 
Action suggested: Adversity should be integrated into the detailed draft decision tree to be 
suggested during the workshop. 
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Question 11: Can specificity (direct effect versus secondary, indirect effect) be used 
as a criterion to analyse potential endocrine disrupting properties? 
23 out of 33 answered ‘yes’ (see Figure 10 below). Consequently specificity will be 
integrated into a preliminary draft decision tree. However, since the IA was only 43.8% and a 
definition of specificity will have to be decided on, further discussion during the workshop is 
regarded as necessary.  
0
5
10
15
20
25
Yes No No preference
 
Figure 10: Results for the question on specificity as a criterion for assessment and decision on ED. 
N=33; deviations from this number can be explained by some participants who did not answer this 
question at all. 
 
Comments from participants: 
• Endocrine disruption may itself be secondary. 
 
• Does it matter to the individual if the damage stuns from a secondary/indirect effect? 
 
Action suggested: Should be discussed in breakout group II. Potentially to be integrated into 
a detailed draft decision tree. 
 
 
Question 12: Can dose dependency be used as a criterion to analyse potential 
endocrine disrupting properties? 
20 out of 33 responders answered ‘yes’ (as presented in Figure 11 below). Since the IA was 
34.4% only, further discussion at the workshop is regarded necessary. 
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Figure 11: Results for the question on dose dependency as a criterion for assessment and decision 
on ED. N=33; deviations from this number can be explained by some participants who did not answer 
this question at all. IA=34.4%. 
 
Comments from participants: 
• Chronic adverse effects generated by low dose endocrine effect can be a result of 
multi-step epigenetical alterations, so that the response can be similar to the results 
seen in carcinogenesis studies, that is, not all animals respond exactly equally but 
respond in a probabilistic way, such as increase in incidence. 
 
• Yes, for a single action. No, for a combination of actions (u-shaped curve?). 
 
Action suggested: Should be discussed in breakout group III. 
 
 
Question 13: Is it justified from a scientific point of view to use the preliminary criteria 
for ED mentioned in the draft regulation (category 3 carcinogen / category 3 
reprotoxicant)? 
Here a majority of participants answered ‘no’ (IA = -86,2%). It is therefore regarded as 
consensus among experts that from a scientific point of view the preliminary criteria for 
decision on the endocrine disrupting potential of substances to be used as plant protection 
products presented in the draft regulation are not appropriate. Consequently, the workshop 
is aimed to consider and suggest other criteria to be used in a tiered approach for 
assessment and decision.  
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Figure 12: Results for the question on specificity the preliminary decision-criteria for ED presented in 
the draft regulation. N=33; deviations from this number can be explained by some participants who 
did not answer this question at all. 
 
Comments from participants: 
• There are more than just 2 sets of endpoints regulated by endocrine mechanisms. 
Alternatively, is a cat3 carc and reprotox proof of an endocrine effect? 
 
Action suggested: No further discussion foreseen since a good level of agreement was 
reached. 
 
Question 14: Should a limit dose concept be considered? 
A majority of participants answered ‘yes’ as presented in Figure 13 below. The IA equalled 
28.6%. 
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Figure 13: Results for the question on consideration of a limit dose concept. N=33; deviations from 
this number can be explained by some participants who did not answer this question at all. 
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Comments from participants: 
• In the absence of resolving the issues of low dose effects, this may not be 
appropriate. 
 
Action suggested: A limit dose concept was considered acceptable by a slight majority. This 
topic should be discussed in breakout group II. Because regulatory and / or political decision 
will be required for integration of this concept into the European plant protection products 
legislation, it might be necessary to also address and discuss this issue in the future. 
 
Question 15: Should we differentiate an alteration of endocrine function observed at 
dose levels causing general toxicity from that caused by a specific action on 
endocrine targets? 
25 out of 33 responders answered ‘yes’ (see Figure 14 below). The IA equals 70%. 
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Figure 14: Results for the question on differentiation between alterations of endocrine function 
observed at dose levels causing general toxicity from that caused by a specific action on endocrine 
targets. N=33; deviations from this number can be explained by some participants who did not answer 
this question at all. 
 
Comments from participants: 
• Yes, if we want to understand them. However, just because something happens at a 
generally toxic dose level does not mean it is unspecific. 
 
Action suggested: No further discussion foreseen. The answer of experts might be seen as 
one recommendation of the workshop. 
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Question 16: Should adverse endocrine effects occurring at or above doses causing 
other general toxicity be regarded as relevant for the decision process? 
A majority of participants answered ‘no’ as presented in Figure 15 below. Since the IA is -
20.7%, there should be a discussion during the workshop. 
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Figure 15: Results for the question on relevance of effects observed at dose levels of general toxicity. 
N=33; deviations from this number can be explained by some participants who did not answer this 
question at all. 
 
Action suggested: Should be discussed in breakout group I or II. 
 
 
Question 17: Can it be justified to limit the regulatory relevance of endocrine effects 
to the hypothalamic-pituitary-gonadal (HPG) axis and the hypothalamic-pituitary-
thyroid (HPT) axis? 
Clearly, limitation of ED effects to only some parts of the endocrine system is not supported 
by workshop participants. Results to this question are presented in Figure 16. The IA is -
59.4%. 
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Figure 16: Results for the question on limiting ED to HPG and HPT axis. N=33; deviations from this 
number can be explained by some participants who did not answer this question at all. IA=-59.4%. 
 
Action suggested: No further discussion foreseen. The clear answer of experts will be seen 
as one recommendation of the workshop. 
 
Question 18: Will it also be necessary to address effects of other parts of the 
endocrine system such as the hypothalamic-pituitary-adrenal axis or the regulation of 
energy metabolism? 
Since this question was closely related to the previous one, non-surprisingly here a majority 
of experts plead for acknowledging effects on all parts of the endocrine system, especially 
the Hypothalamic-Pituitary-Adrenal (HPA) axis and the regulation of energy metabolism. 
Results of this question are presented in Figure 17 below. The IA was 78.6%. 
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Figure 17: Results for the question if effects of other parts of the endocrine system will have to be 
acknowledged. N=33; deviations from this number can be explained by some participants who did not 
answer this question at all. IA=78.6%. 
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Comments from participants: 
• Central nervous system is sensitive to, not only estrogenic/ antiandrogenic, but also 
to other analogs/ inhibitors of neurotransmitters. 
 
Action suggested: The answer of experts might be seen as one recommendation of the 
workshop. However, since the extent of effects and mechanisms acknowledged will have to 
be discussed, this question is considered for breakout group II. 
 
 
Question 19: Are endocrine effects relevant for acute toxicity and for setting an Acute 
Reference Dose? 
Participants agreed as presented in Figure 18. The IA was 40.6%. 
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Figure 18: Results for the question on acute reference dose. N=33; deviations from this number can 
be explained by some participants who did not answer this question at all. 
 
Comments from participants: None. 
 
Action suggested: Should be left open for future discussion, e.g. at another workshop 
focussing on ARfD. 
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Question 20: Should we classify and label substances with endocrine disrupting 
properties on the basis of existing categories (e. g for carcinogenicity, reprotoxicity 
or specific target organ toxicity), or is it necessary to adopt a new system for 
classification and labelling of endocrine disrupting substances? 
A majority of participants agreed, that classification and labelling should be performed on the 
basis of the existing system (15 participants to 7 who preferred a new system). See Figure 
19 below for an overview on answers. The IA was 30.8%. 
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Figure 19: Results for the question on classification and labelling of endocrine effects. N=33; 
deviations from this number can be explained by some participants who did not answer this question 
at all. IA=30.8%. 
 
Comments from participants: 
• The existing classifications refer to endpoints rather than mechanism and can be 
used regardless of the mode of action which causes them. 
 
Action suggested: Should be discussed in breakout group IV. Classification and labelling of 
substances is of great importance but since regulatory and / or political action is required this 
topic might also be left open for future discussion.  
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Question 21: Should newly discovered mechanisms of ED (e.g. hormone sensitisers) 
be integrated into the concept? 
21 participants answered ‘yes’, while only a small number (4) answered ‘no’ or had no 
preference (4) as shown in Figure 20. The IA was high and equalled 60.7%. 
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Figure 20: Results for the question on relevance of newly discovered (molecular) mechanisms of ED 
like hormonal sensitizers. N=33; deviations from this number can be explained by some participants 
who did not answer this question at all. IA=60.7%. 
 
Comments from participants: None 
 
Action suggested: Newly discovered mechanisms like hormonal sensitizers will clearly have 
to be acknowledged also for the sake of consumer protection. Since various mechanisms 
have been identified and more will surely be discovered as science progresses, this topic is 
suggested to be left open for future discussion, e.g. at another workshop on molecular 
mechanisms of ED. 
 
 
Question 22: Is a mode of action analysis a feasible approach in the field of endocrine 
disruption? 
A clear majority of participants agreed that a mode of action analysis is feasible also in the 
field of ED. 26 of 33 responders stated ‘yes’ while only 5 answered ‘no’ as presented in 
Figure 21 below. The IA was 67.7%, so mode of action is considered to be integrated into a 
draft detailed decision tree. 
BfR Workshop Report  
 
 
43 
0
5
10
15
20
25
30
Yes No No preference
 
Figure 21: Results for the question on feasibility of mode of action analysis. N=33; deviations from this 
number can be explained by some participants who did not answer this question at all. 
 
Comments from participants: 
• Yes, not only is it feasible, but it is important if we are going to perform risk 
assessments that incorporate cumulative aspects of co-exposure. 
 
Action suggested: To be integrated into a more detailed draft decision tree. 
 
Question 23: Is the IPCS mode of action framework (Boobis et al. 2008) feasible for 
analysing relevance to humans? 
While a majority in general agreed on the IPCS MOA framework, nearly as many 
participants had no preference on this question. As a consequence the IA was low and 
equalled 39.3%. 
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Figure 22: Results for the question on feasibility of the IPCS mode of action framework for ED effects. 
N=33; deviations from this number can be explained by some participants who did not answer this 
question at all. 
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Comments from participants: 
• Yes, but should be updated with regard to endocrine effects. 
 
Action suggested: Should be discussed in breakout group IV. 
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Annex IV: Results of the individual breakout groups 
 
Breakout group I – Informative value of studies/methods 
1st question for discussion: Are the core studies laid down in point 5.3, 5.5 and 5.6 of Table 1 
sufficient to provide any evidence on potential adverse effects on the endocrine system in 
mammals?  
  The groups answer was clearly YES, the core studies are sufficient to provide some 
evidence on potential adverse effects, but it is still not known, if all possible aspects 
are captured.  
 This is, however, not only a problem of ED, but also of other endpoints such 
as immunotoxicity etc. 
 It was speculated that interpretation of study-results might differ between 
researchers and regulatory agencies. 
 It was asked how to improve the methods and what could be new endpoints 
which could be included into existing guidelines. 
 Routine testing can not find all possible effects, therefore we have to ask 
scientist.   
 
2nd question for discussion: Are existing study designs (OECD guidelines etc.) 
comprehensive enough to detect endocrine effects? 
 There were concerns that the existing study designs are not comprehensive enough 
to detect adverse effects which might be caused by endocrine disruption in 
mammalian test organisms.  
 However, the lack of concrete examples which are not captured by the test 
guidelines was criticized and research scientists were asked to come forward with 
such practical examples. 
 Until practical examples have been provided, the question remains what additional 
endpoints should be included into existing guidelines? 
 
3rd question for discussion: Should adverse endocrine effects occurring at or above 
doses causing other general toxicity be regarded as relevant for the decision process? 
 Endocrine effects at clearly higher doses than those causing general toxicity 
might not be regarded as endocrine disruptive, if they are considered to be 
secondary. These substances should go to regular risk assessment under the EU 
PPP regulation. 
 If we have evidence that endocrine disruption is the critical effect based on 
mechanistic studies, then YES. 
BfR Workshop Report  
 
 
46 
 This question can’t be solved, if the consideration of exposure in humans is 
excluded, e.g. by combining hazard identification and elements of risk 
assessment, in the decision making process. 
 
Toxicological data for an example pesticide were provided and the criteria and decision tree 
were tested using this exemplary compound. The breakout group analyzed the example and 
found the criteria and decision tree useful. It was possible to establish a mode of action in 
accordance with the IPCS mode of action framework. Based on this mode of action it was 
decided that the effects observed would be relevant for humans. Based on the assessment 
and decision criteria it was also concluded that the example provided was an endocrine 
disruptor. 
 
The following final recommendations were suggested by group I:  
 Core principles upon which the group could agree: 
 The answers to the 3 questions 
 The example is an ED 
 A MoA could be established in the stepwise approach 
 The decision tree is considered useful 
 Major issues of discussion and open questions were: 
 Do we expect „low dose“ effects in reality for all ED? 
 What is negligible exposure for operators, bystanders, residents and 
consumers? 
 Different wording on ED under PPP and REACH 
  Recommendations were: 
1. Low dose workshop is recommended  
2. Go forward with the conclusion of the workshop to the commission. 
3. Consider extension of existing guidelines to better address this issue. 
 The next steps recommended were: 
1. More experimental work is needed to investigate and reproduce low dose 
effects. 
2. OECD and other bodies should also consider the relevance of this approach. 
3. Call for practical examples that were not detected in routine studies 
 
Breakout group II – Targets and mechanisms of ED  
1st question for discussion: Can specificity be used as a criterion to analyze potential 
endocrine disrupting properties? 
 Criteria for specificity might be: 
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 The crucial issue of endocrine disruption was regarded generally as whether 
the effect is ultimately a receptor-mediated event. 
 An effect should not be regarded as being non-specific or not relevant  purely 
on the basis of being secondary. E. g., liver enzyme induction may lead to 
alterations in circulating hormone levels.  
 In this context two new questions were raised: Can the dose at which an 
endocrine adverse effect is observed be used as a criterion for specificity? 
Can effects occurring at high doses (e. g at which general toxicity or other 
forms of toxicity occur) be regarded as relevant for the regulatory decision 
process? 
 An endocrine adverse effect occurring above the dose level at which a 
different form of toxicity is observed, would be expected to be covered by 
regulation due to the fact that the apparently more sensitive effect (caused by 
other mechanisms of toxicity) would be the starting point for the derivation of 
reference values. 
 
2nd question for discussion: Should a limit dose concept be considered? 
 This question was clearly answered yes.  
 The limit dose concept is already established in current testing protocols of animal 
apical studies (1000 mg/kg bw/d).  
 
3rd question for discussion: Will it also be necessary to address effects of other parts of the 
endocrine system such as the hypothalamic-pituitary-adrenal axis or the regulation of energy 
metabolism?  
 This question was clearly answered yes.  
 
The following final recommendations were suggested by group II:  
 There was concern that with current data sets, endocrine effects might be missed for 
certain compounds in the lower dose range, e. g. concerning particularly sensitive 
stages of pre-natal and neo- or postnatal development. These effects in the low dose 
range might turn out to be the most relevant from a health perspective. It was 
considered that, triggered by evidence, to encourage improvement of testing, 
particularly developmental toxicity testing in respect to the low dose range. 
(Amendment of existing guidelines). 
 To avoid overlooking a particular effect that was mediated by a mechanism that 
operates at a low dose level (below a “traditional” NOAEL) potentially related to 
endocrine disruption, it will be necessary in regulatory toxicology to further develop, 
BfR Workshop Report  
 
 
48 
validate and apply „new“ methodology (e. g. array approaches) to more 
comprehensively identify and interprete additional mechanistic (receptor mediated) 
effects. 
 
Breakout group III – Dose relevance and criteria for adverse effects in animal studies  
1st question for discussion: How to define adverse? 
 Recommended definition (WHO/IPCS 2004): A change in morphology, physiology, 
growth, development or lifespan of an organism which results in impairment of 
functional capacity or impairment of capacity to compensate for additional stress or 
increased susceptibility to the harmful effects of other environmental influences. 
 Acceptable definition; some aspects are difficult to apply/implement with current TGs. 
 
2nd question for discussion: Can dose dependency be used as a criterion to analyze 
potential endocrine disrupting properties? 
 Yes, in principle; every biological effect is dose-dependent; under current TGs it is 
difficult to characterize non-monotonic dose response curves that are typical for 
hormonally active compounds. As a consequence if there is an indication of ED at 
any dose tested this should trigger examinations at lower dose levels/more 
appropriate dose levels and additional endpoints. 
 
3rd question for discussion: What would be an appropriate low dose level in animal studies? 
 Definitions on an absolute basis are not helpful; we need to have case-by-case 
decisions for each compound by taking into account kinetic information, human 
exposure levels, apparent NOAELs and mechanistic data 
 
Toxicological data for an example pesticide were provided and the criteria and decision tree 
were tested upon this example. The breakout group analysed the example and found the 
criteria and decision tree useful with the following modifications: 
 Biological relevance should be part of the decision on adversity; the box should be 
removed. 
 We need to change the Box Mode of Action to Is there a relationship to an endocrine 
mechanism? If no, the substance is not an ED and an exit should be provided at this 
point. If yes, proceed to the next step. If uncertain, ask for more data. 
 
The following final recommendations were suggested by group III:  
 Major issues of discussion and open questions were: 
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 „Adaptive“ effects that go back to „normal“ and developmental delays may  be 
a sign for ED; can short-term functional changes without long-term 
consequences be considered to be non-adverse? 
 Biomarkers vs. adverse effects 
 Need for confirmation of low dose effects? What happens at low doses vs. 
high doses of ED? 
 Shapes of dose-response curves; low dose: to define or not? 
 Future vs. existing data requirements; what data can we get already today? 
 Evidence in vivo vs. in vitro 
 Recommendations were: 
 Study designs need to incorporate appropriate number of dose levels to 
determine a dose-dependency for relevant endpoints.  
 For suspected ED use additional dose level(s) in main study (Generation 
study) to cover low dose range (TG requires a minimum of 3 doses) 
 Take dose-response curve into account, whether linear or non-monotonic 
 Concentrate on developmental exposure and life-time assessment  
 In the future, detection of „change in state“ needs to be included that render 
organism more susceptible to environmental influences 
 The next steps recommended were: 
 Look into existing guidelines and guidelines presently under development to 
decide how practical improvements/new endpoints for all major endocrine 
tissues could be incorporated to detect ED 
• Sexual dimorphic development 
• Endpoints for neurohormonal toxicity 
• Endpoints for Metabolic Syndrome 
• Endpoints for HPA 
 In the data requirements if an extended one-generation study is conducted it 
should as mandatory include DIT and DNT cohorts. 
 Discuss this with the Commission 
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Breakout group IV – Human relevance of evidence for endocrine disruption 
1st question for discussion: What is relevance to humans? 
 The default assumption is relevance; it can be rebutted with additional data. 
 Relevance is a qualitative call – at the first stage, not related to dose. 
 Mechanism of action is the recommended context for determining relevance (draw 
upon example) - we recommend moving to a regulatory system that ensures 
availability of mechanistic data.10 
 Experimental phenotype is not the basis for determining relevance by itself.  
 A central problem is that the discussion is based on endpoints gained from the 
toxicity studies but that the definition of EDC is mechanism-based. 
 For cancer and reproductive endpoints, decisions might be made as to relevance 
based on dose or phenotype, but for EDCs this is not feasible since endocrine 
systems are conserved across species. 
 IPCS recommendations are not generally feasible since we do not usually have 
information on mechanism.  
 Group IV proposed the following changes to the relevance for humans framework for 
the decision tree: 
 Step I: Look at the endpoints from standard tests for signals of ED including 
changes in distributions of the endpoint or increases in variability 
 Step II: Evaluation of relevant ED endpoints 
 Step III: Analysis of ED MoA (and mechanistic data if available) 
 Step IVa: if MoA for the endpoint is ED and relevant to endpoint in humans, 
then it is an EDC (and of high concern) 
 Step IVb: if the MoA is ED but endpoint affected in standard test not relevant 
to humans, it is still an EDC (and may be of high concern) 
  Critical points:  
 Effect might be missed (e.g. low incidence) – size of studies 
 Look at effects on variability and ends of distribution 
 How do we consider adversity? 
 How do we consider potency? 
 Mechanism or mode of action? – mechanism should be basis for excluding 
relevance to humans 
 
2nd question for discussion: Should we classify and label substances with endocrine 
disrupting properties on the basis of existing categories (e. g for carcinogenicity, reprotoxicity 
                                               
10
 Mechanistic data are, however, already required by directive 91/414/EEC. 
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or specific target organ toxicity), or is it necessary to adopt a new system for classification 
and labelling of endocrine disrupting substances? 
 In the next phase it was regarded to be necessary to develop a classification system 
for endocrine disrupting chemicals considering issues such as adversity etc. 
  It was proposed to call it Endocrine Disrupting Chemicals or Endocrine Toxicants. 
 It was asked whether a system possibly like carcinogens or reprotox – or a yes/no 
classification or level of concern should be recommended. 
 A critical point was the question what to do about interim criteria. 
 Interim criteria are not scientifically based (to consider C3/R3 substances to 
be EDs) 
 
3rd question for discussion: What is a negligible exposure level? 
 Critical points: A MRL of 0.01 mg/kg food for all compounds is not a health-based 
scientific decision criterion. 
 
Further topics discussed related to testing of substances with an endocrine disrupting 
potential: 
 Obtaining information in the low dose range (important for EDCs) 
 If the tests were not conducted within the known or estimated range of likely human 
exposure: 
 for existing compounds  
 1st step: Biomonitoring to determine range of actual human internal dose was 
recommended 
 2nd step: It was suggested to conduct limited toxicokinetics (or use kinetic 
data from respective studies available for plant protection products) in 
experimental species to establish exposure that produces this range of 
internal dose 
 3rd step: Additionally it was proposed to conduct studies in this dose range. 
 
 new chemicals  
 It was suggested to use the apparent NOAEL from the standard tests to 
establish a dose range that is at least 1000 fold lower (learn from experience) 
for further testing.  
 This may be refined with further exposure data from producer or after 
chemical comes into use. 
 It was proposed to look for body wt and the effect observed or suspected 
based upon earlier data in the high dose range. 
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Toxicological data for an example pesticide were provided and the criteria and decision tree 
were tested upon this example. The breakout group discussed the example and found it of 
great value for discussion. The following recommendations were made with respect to the 
decision tree: 
 Test the criteria and decision tree with known positive ED chemicals and known 
negative ED chemicals. 
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Annex V: Originally proposed decision tree 
The following tiered approach and decision tree were suggested by BfR in preparation for 
the workshop. They were modified to account for recommendations made during the 
workshop. The originals are presented here to allow a better understanding of changes. 
 
 
Figure 3: Originally proposed tiered approach. This approach consisted of five steps, starting with the 
evaluation of all available data and exclusion of cat 1A and 1B CMR substances according to the 
Globally Harmonized System (GHS) on Classification, Labelling and Packaging as laid down in Reg. 
(EC) No. 1272/2008. Prior to endpoint based analysis in step III a mechanism based analysis was 
suggested to be performed in step II. A mode of action analysis to determine human relevance was 
considered to be conducted in a fourth step before finally deciding on endocrine disrupting properties 
and negligible exposure in step five.  
 
 
 
Analysis of endocrine disruption in animals 
(mechanism-based, adverse key effects) 
Evaluation of relevant endpoints  
(endpoint-based regulatory relevance)  
Human relevance of postulated mode of action 
(MOA analysis in animals vs. humans) 
Decision: ED according to the EC Regulation  
(Substance with endocrine disrupting properties that 
may cause adverse effects in humans) 
→ Decision on negligible exposure 
Evaluation of all available data 
 (exclusion of Cat 1A or Cat 1B (GHS) carcinogens and 
reprotoxicants) 
BfR Workshop Report  
 
 
54 
 
Figure 4: Original draft decision tree. This decision tree suggested several criteria for decision on ED 
including adversity, specificity, biological and human relevance. It also suggested integrating the 
respective IPCS framework into the decision on human relevance. 
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Annex VI: Abbreviations 
 
ARfD  Acute Reference Dose 
BfR  Bundesinstitut für Risikobewertung (German Federal Institute for Risk  
Assessment) 
CMR  Carcinogenic, Mutagenic, or Reprotoxic 
DIT  Developmental Immunotoxicity 
DNT  Developmental Neurotoxicity 
EC  European Community 
ECETOC European Centre for Ecotoxicology and Toxicology of Chemicals 
ED  Endocrine Disruption, Endocrine Disruptor 
EDC  Endocrine Disrupting Chemical 
EEC  European Economic Community 
EFSA  European Food Safety Authority 
EPA  Environmental Protection Agency 
EU  European Union 
GHS  Globally Harmonised System 
HPA  Hypothalamic-Pituitary-Adrenal 
HPG  Hypothalamic-Pituitary-Gonadal 
HPT  Hypothalamic-Pituitary-Thyroid 
IA  Index of Agreement 
IPCS  International Programme on Chemical Safety 
MoA  Mechanism / Mode of Action 
MOE  Margin of Exposure 
MRL  Maximum Residue Levels 
NGO  NON-Governmental Organisation 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NRC  National Research Council 
OECD  Organisation for Economic Co-operation and Development 
PPP  Plant Protection Product 
RE  Repeated Exposure 
REACH Registration, Evaluation, Authorisation of Chemicals 
SE  Single Exposure 
STOT  Specific Target Organ Toxicity 
TG  Testing Guideline 
TTC  Threshold of Toxicological Concern 
WHO  World Health Organization 
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